Neurocrine Biosciences (NASDAQ: NBIX) reported Q3 EPS of $0.64, $0.05 better than the analyst estimate of $0.59. Revenue for the quarter came in at $296 million versus the consensus estimate of $296.65 million.

For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.